Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $45.25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $45.25.

A number of research firms have weighed in on FDMT. Leerink Partners restated an “outperform” rating and set a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Finally, Chardan Capital boosted their price objective on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, September 19th.

4D Molecular Therapeutics Stock Down 1.2 %

Shares of NASDAQ FDMT opened at $10.83 on Monday. The stock’s 50-day simple moving average is $15.21 and its two-hundred day simple moving average is $21.88. 4D Molecular Therapeutics has a twelve month low of $9.44 and a twelve month high of $36.25. The firm has a market capitalization of $559.94 million, a P/E ratio of -4.44 and a beta of 2.80.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.90 million. As a group, research analysts anticipate that 4D Molecular Therapeutics will post -2.75 EPS for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, CEO David Kirn sold 12,923 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total transaction of $290,638.27. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO David Kirn sold 12,923 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $22.49, for a total transaction of $290,638.27. Following the transaction, the chief executive officer now owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Scott Bizily sold 1,750 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $27.11, for a total value of $47,442.50. Following the completion of the sale, the insider now owns 6,781 shares of the company’s stock, valued at approximately $183,832.91. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,169 shares of company stock worth $396,146. Insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its position in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares in the last quarter. Quest Partners LLC raised its holdings in 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares in the last quarter. Entropy Technologies LP purchased a new position in 4D Molecular Therapeutics during the first quarter valued at $239,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of 4D Molecular Therapeutics by 93.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,579 shares of the company’s stock valued at $305,000 after buying an additional 4,628 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $344,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.